Vaporized Nicotine and Autonomic Control

Michigan Technological University

Status and phase

Completed

Early Phase 1

Conditions

Electronic Cigarette Use

Treatments

Device: Electronic Cigarette containing nicotine

Device: Electronic Cigarette without nicotine

Study type

Interventional

Funder types

Other

Identifiers

NCT04613609

M1747

Details and patient eligibility

About

E-cigarettes are marketed as an alternative to smoking for those who want to decrease the health risks of tobacco. Tobacco cigarettes increase heart rate (HR) and arterial pressure, while reducing muscle sympathetic nerve activity (MSNA) through sympathetic baroreflex inhibition. The acute effects of e-cigarettes on arterial pressure and MSNA have not been reported: our purpose was to clarify this issue. Using a randomized crossover design, participants inhaled on a JUUL containing nicotine (59 mg/ml) and a similar placebo e-cigarette (0 mg/ml).

Enrollment

16 patients

Sex

All

Ages

21 to 40 years old

Volunteers

Accepts Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

Exclusion Criteria:

Individuals with a history of hyperthyroidism
Women currently taking oral contraceptives, are pregnant or breast-feeding, or trying to become pregnant
Individuals currently taking prescription drugs.
Individuals with respiratory illnesses (e.g., asthma, chronic obstructive pulmonary disease, reactive airway disease, etc.)
Individuals with hypertension (systolic >130 and/or diastolic > 80).
Individuals with a history of tobacco or vaporized nicotine use.
Individuals who have been diagnosed with diabetes
Individuals who are under the age of 18 or over the age of 40